| Theme | Treatment of Acid‒related Diseases -- the Past, Present and Future | |
|---|---|---|
| Title | Gastric Carcinoid Due to Long—term Inhibition of Gastric Acid Secretion | |
| Publish Date | 2017/02 | |
| Author | Yuichi Sato | Division of Endoscopy, Niigata University Medical and Dental Hospital |
| Author | Yuki Nishigaki | Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University |
| Author | Ken‒ichi Mizuno | Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University |
| Author | Satoru Hashimoto | Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University |
| Author | Junji Yokoyama | Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University |
| Author | Shuji Terai | Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University |
| [ Summary ] | According to a recent systematic review, long‒term PPI therapy induced ECL-cell hyperplasia, but no gastric carcinoids were found. Therefore, it is thought that the incidence rates of gastric carcinoid due to long‒term PPI treatment could be approximately zero. Additionally, it is unknown whether long‒term administration of P‒CAB, a new potent acid suppressor, increases the risk of developing gastric carcinoids. However, there is speculation that hypergastrinemia could predispose to, but may not be sufficient alone to cause the formation of gastric carcinoids. Nonetheless, further studies will be necessary to investigate the relationship between hypergastrinemia and gastric carcinoids. | |